In a report released today, Emily Bodnar from H.C. Wainwright upgraded MiNK Therapeutics to a Buy, with a price target of $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar has given her Buy rating due to a combination of factors that highlight the potential of MiNK Therapeutics’ ongoing clinical trials. The company has shown promising initial translational data from its Phase 2 trial in refractory gastroesophageal cancer, with notable increases in key immune cells and cytokines following treatment. These early indicators suggest potential therapeutic activity, although further data on primary and secondary endpoints are awaited to confirm efficacy.
Additionally, the initiation of an externally funded trial for the prophylactic treatment of graft versus host disease (GvHD) in the second half of 2025 adds to the company’s growth prospects. The trial aims to evaluate the effectiveness of agenT-797 in preventing GvHD post-allogeneic hematopoietic stem cell transplantation, addressing a significant unmet medical need. Given the substantial decline in MiNK’s stock price, which is now well below the price target, and the anticipated catalysts from upcoming trial data, Bodnar sees a compelling opportunity for investment, leading to the upgrade from Neutral to Buy.